Survivorship · Heart protection
Metabolic health after cancer, in the service of protecting your heart.
Metabolic health is not a separate program here. It is one part of survivorship care, because the changes cancer treatment causes to weight, muscle, glucose, lipids and blood pressure are among the strongest drivers of long-term cardiovascular risk in survivors.
Straight answer
After cancer treatment, many survivors develop new metabolic problems that raise the risk of heart disease. Heart disease, not cancer recurrence, becomes the leading cause of death for several survivor groups over time. Monitoring and treating metabolic risk is one of the most effective ways to protect the heart after cancer.
What changes after treatment
Treatment-related weight and body-composition change
Steroids, androgen-deprivation therapy, endocrine therapy and reduced activity during treatment shift the ratio of muscle to fat. Losing muscle while gaining fat raises cardiovascular risk even when the number on the scale looks stable.
Glucose and insulin resistance
Corticosteroids, some targeted agents and mTOR inhibitors can raise blood glucose. New or worsening insulin resistance after treatment is common and often goes unmonitored once oncology visits taper off.
Lipids and blood pressure
Androgen-deprivation therapy, aromatase inhibitors and several targeted therapies change lipid profiles and blood pressure. These are modifiable, and they compound anthracycline or radiation-related cardiac injury.
Sarcopenia and deconditioning
Muscle loss after treatment reduces functional capacity and worsens metabolic control. Rebuilding lean mass is a cardiac-protective intervention, not a cosmetic one.
What to do about it
Know your baseline
Blood pressure, fasting glucose or A1c, a lipid panel, and weight with waist measurement in the first year after treatment ends.
Rebuild muscle before chasing the scale
Resistance training two to three times weekly plus adequate protein protects lean mass and supports glucose control.
Track it alongside cardiac surveillance
Metabolic numbers belong on the same calendar as echocardiograms and cardio-oncology follow-up, not on a separate track.
Bring it to your primary care visit
Print a summary and ask who is responsible for each number now that active treatment has ended.
GLP-1 education series
Ten modules with slides and video on GLP-1 therapy in survivorship care.
Cardio-oncology pathway
How heart risk is assessed and followed after cancer treatment.
Start the survivorship guide
Plain-language next steps for the first year after treatment.
Educational information only. It does not replace advice from your oncology or primary care team, and no treatment decision should be made from this page alone.